115 related articles for article (PubMed ID: 37899263)
1. Association between BRCA Gene Variants and the Response to Modified FOLFIRINOX in Patients with Unresectable Pancreatic Cancer.
Horiguchi S; Matsumoto K; Morimoto K; Matsumi A; Terasawa H; Fujii Y; Yamazaki T; Tsutsumi K; Kato H
Acta Med Okayama; 2023 Oct; 77(5):517-525. PubMed ID: 37899263
[TBL] [Abstract][Full Text] [Related]
2. Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer.
Golan T; Barenboim A; Lahat G; Nachmany I; Goykhman Y; Shacham-Shmueli E; Halpern N; Brazowski E; Geva R; Wolf I; Goldes Y; Ben-Haim M; Klausner JM; Lubezky N
Ann Surg Oncol; 2020 Oct; 27(10):3963-3970. PubMed ID: 32314163
[TBL] [Abstract][Full Text] [Related]
3. BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients.
Park JH; Jo JH; Jang SI; Chung MJ; Park JY; Bang S; Park SW; Song SY; Lee HS; Cho JH
Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008403
[TBL] [Abstract][Full Text] [Related]
4. Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
Sorscher S; Ramkissoon S
Oncologist; 2021 Nov; 26(11):916-918. PubMed ID: 34309133
[TBL] [Abstract][Full Text] [Related]
5. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel.
Saito K; Nakai Y; Takahara N; Ishigaki K; Suzuki Y; Inokuma A; Noguchi K; Kanai S; Sato T; Hakuta R; Saito T; Hamada T; Mizuno S; Kogure H; Ijichi H; Tateishi K; Koike K
Invest New Drugs; 2021 Apr; 39(2):605-613. PubMed ID: 33094362
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer.
Hino K; Nishina T; Numata Y; Asagi A; Inoue T; Yoshimatsu M; Sakaguchi C; Nakasya A; Nishide N; Kajiwara T; Terao T; Nadano S; Marui K; Okujima Y; Kokubu M; Imamura Y; Kanemitsu K; Koizumi M; Kumagi T; Hiasa Y; Hyodo I
Intern Med; 2022; 61(15):2255-2261. PubMed ID: 35908959
[TBL] [Abstract][Full Text] [Related]
7. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing.
Lee K; Yoo C; Kim KP; Park KJ; Chang HM; Kim TW; Lee JL; Lee W; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Shin SH; Hwang DW; Song KB; Lee JH; Kim SC; Ryoo BY
Invest New Drugs; 2018 Feb; 36(1):163-169. PubMed ID: 28782087
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes.
Militello AM; Orsi G; Cavaliere A; Niger M; Avallone A; Salvatore L; Tortora G; Rapposelli IG; Giordano G; Noventa S; Giommoni E; Bozzarelli S; Macchini M; Peretti U; Procaccio L; Puccini A; Cascinu S; Montagna C; Milella M; Reni M
Cancer Chemother Pharmacol; 2023 Dec; 92(6):501-510. PubMed ID: 37725113
[TBL] [Abstract][Full Text] [Related]
9. DNA damage repair deficiency as a predictive biomarker for FOLFIRINOX efficacy in metastatic pancreatic cancer.
Palacio S; McMurry HS; Ali R; Donenberg T; Silva-Smith R; Wideroff G; Sussman DA; Rocha Lima CMS; Hosein PJ
J Gastrointest Oncol; 2019 Dec; 10(6):1133-1139. PubMed ID: 31949930
[TBL] [Abstract][Full Text] [Related]
10. Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON Study.
Nakazawa J; Tsuruta N; Shimokawa M; Kawahira M; Arima S; Ido A; Koga F; Ueda Y; Komori A; Otsu S; Fukahori M; Makiyama A; Taguchi H; Honda T; Shibuki T; Nio K; Ide Y; Ureshino N; Mizuta T; Otsuka T; Shirakawa T; Mitsugi K
Oncology; 2023; 101(1):22-31. PubMed ID: 36195058
[TBL] [Abstract][Full Text] [Related]
11. Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review.
Hohla F; Hopfinger G; Romeder F; Rinnerthaler G; Bezan A; Stättner S; Hauser-Kronberger C; Ulmer H; Greil R
Int J Oncol; 2014 Jan; 44(1):319-26. PubMed ID: 24247204
[TBL] [Abstract][Full Text] [Related]
12. Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study.
Tezuka S; Ueno M; Kobayashi S; Hamaguchi T; Yamachika Y; Oishi R; Nagashima S; Fukushima T; Morimoto M; Shin M
Pancreatology; 2022 Sep; 22(6):789-796. PubMed ID: 35705458
[TBL] [Abstract][Full Text] [Related]
13. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
14. Germline BRCA2 variants in advanced pancreatic acinar cell carcinoma: A case report and review of literature.
Lee CL; Holter S; Borgida A; Dodd A; Ramotar S; Grant R; Wasson K; Elimova E; Jang RW; Moore M; Kim TK; Khalili K; Moulton CA; Gallinger S; O'Kane GM; Knox JJ
World J Gastroenterol; 2022 Dec; 28(45):6421-6432. PubMed ID: 36533108
[TBL] [Abstract][Full Text] [Related]
15. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.
Javle M; Shacham-Shmueli E; Xiao L; Varadhachary G; Halpern N; Fogelman D; Boursi B; Uruba S; Margalit O; Wolff RA; Golan T
JAMA Oncol; 2021 May; 7(5):693-699. PubMed ID: 33662100
[TBL] [Abstract][Full Text] [Related]
16. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
Shimmura H; Kuramochi H; Jibiki N; Katagiri S; Nishino T; Araida T
Jpn J Clin Oncol; 2019 Dec; 49(11):1049-1054. PubMed ID: 31612916
[TBL] [Abstract][Full Text] [Related]
17. Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.
Queck A; Elango S; Koch C; Walter D; Schmidt J; Trebicka J; Trojan J; Pession U; Finkelmeier F; Waidmann O
Oncol Res Treat; 2022; 45(3):79-87. PubMed ID: 34875671
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
[TBL] [Abstract][Full Text] [Related]
19. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.
Boone BA; Steve J; Krasinskas AM; Zureikat AH; Lembersky BC; Gibson MK; Stoller RG; Zeh HJ; Bahary N
J Surg Oncol; 2013 Sep; 108(4):236-41. PubMed ID: 23955427
[TBL] [Abstract][Full Text] [Related]
20. Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutation.
Okada K; Uemura K; Okamoto W; Sumiyoshi T; Shintakuya R; Otsuka H; Serikawa M; Ishii Y; Arihiro K; Takahashi S
Clin J Gastroenterol; 2023 Apr; 16(2):283-288. PubMed ID: 36574187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]